<- Go Home
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Market Cap
$52.0M
Volume
24.7K
Cash and Equivalents
$6.8M
EBITDA
-$6.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$606.5K
Profit Margin
33.62%
52 Week High
$9.60
52 Week Low
$1.53
Dividend
N/A
Price / Book Value
4.19
Price / Earnings
-5.91
Price / Tangible Book Value
7.65
Enterprise Value
$45.4M
Enterprise Value / EBITDA
-7.51
Operating Income
-$6.3M
Return on Equity
74.87%
Return on Assets
-33.66
Cash and Short Term Investments
$6.8M
Debt
$214.3K
Equity
$12.5M
Revenue
$1.8M
Unlevered FCF
-$2.3M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium